Isoforms of hyaluronidases can be a predictor of a prostate cancer of good prognosis

de Sá, Vanessa K.; Canavez, Flávio C.; Silva, Iran A.; Srougi, Miguel; Leite, Katia R.M.

doi:10.1016/j.urolonc.2008.04.013

« Previous Next »Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 377-381, July 2009

Isoforms of hyaluronidases can be a predictor of a prostate cancer of good prognosis

Vanessa K. de Sá, B.S.
- Laboratory of Medical Investigation–LIM55 Medical School, Urology Department, São Paulo University, São Paulo, Brazil
Flávio C. Canavez, Ph.D.
- Genoa Biotechnology, São Paulo, Brazil
Iran A. Silva, B.S.
- Laboratory of Medical Investigation–LIM55 Medical School, Urology Department, São Paulo University, São Paulo, Brazil
Miguel Srougi, M.D., Ph.D.
- Laboratory of Medical Investigation–LIM55 Medical School, Urology Department, São Paulo University, São Paulo, Brazil
Katia R.M. Leite, M.D., Ph.D.
- Laboratory of Medical Investigation–LIM55 Medical School, Urology Department, São Paulo University, São Paulo, Brazil
- Genoa Biotechnology, São Paulo, Brazil
- Corresponding author. Tel.: +55-11-3069 8080; fax: +55-11-3231 2249

Received 28 January 2008; received in revised form 11 April 2008; accepted 17 April 2008. published online 22 July 2008.

Abstract

Introduction

Hyaluronidases (HAases) are enzymes related to cancer progression. Isoforms of HAases have been described as products of alternative splicing responsible for differences in enzyme activity. The heterogeneity of HAase expression has been identified in tumors and could be related to the differences in their biological behavior.

Methods

Thirty-seven patients subjected to radical prostatectomy for prostate cancer were divided into 2 groups for the analyses: Low (≤6–18) and high (≥7–19) Gleason score and tumor behavior; recurrence 15 and nonrecurrence 22, mean follow-up 52.6 months.

Conclusion

A profile of HAase related to low Gleason score and non-tumor recurrence was characterized by expression of HYAL3-v1, HYAL1-v3, and HYAL3-v2. More studies should be made in order to confirm with larger series.

Keywords: Hyaluronidases, Hyaluronan, Alternative splicing, Prostate cancer, Prognosis